References
  1. https://covid19.who.int/
  2. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020;8(4):e24.
  3. Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J Crit Care. 2020;58:27-28.
  4. Schmidt M, Tachon G, Devilliers C, et al. Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med. 2013;39(5):838-46.
  5. Bonow RO, Fonarow GC, O’gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol. 2020
  6. Klok FA, Kruip MJHA, Van der meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020
  7. Li X, Guo Z, Li B, et al. Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China. ASAIO J. 2020
Figure1 : Patient selection, evaluation, and treatment strategies. ARDS= acute respiratory distress syndrome, CKD=chronic kidney disease, CHF=congestive heart failure, PEEP=positive end expiratory pressure, ECMO=extracorporeal membrane oxygenation, PAO2=partial pressure of oxygen , PCO2=partial pressure of carbon dioxide, DO2 = oxygen delivery. VO2 = oxygen consumption. V/Q = ventilation/perfusion.